The dose selection and ASPENOVA initiation de-risk the regulatory pathway for azenosertib. The DENALI topline readout by year-end 2026 is the next major catalyst — positive data could drive significant upside given the 50% PROC patient population with no approved biomarker-specific therapy. Monitor for FDA feedback on accelerated approval and any partnership or financing announcements given the cash runway into late 2027.
Price Chart
Executive Summary
Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib monotherapy in Cyclin E1-positive PROC, advancing the DENALI Phase 2 trial toward a topline readout by year-end 2026, which could support an accelerated approval pathway. Cash of $211.8M provides runway into late 2027, funding key milestones including the ASPENOVA Phase 3 trial initiation.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.50 vs consensus -$0.52 (4.5% beat)
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC
- DENALI Part 2 topline readout expected by year-end 2026, potentially supporting accelerated approval
- ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed
- Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
- R&D expenses $28.7M in Q1 2026 vs $27.2M in Q1 2025; total operating expenses $37.9M vs $45.6M
- Net loss $35.4M in Q1 2026 vs $48.3M in Q1 2025
Financial Impact
EPS beat of $0.02 per share; cash burn of ~$34M in Q1 2026; no revenue reported
Risk Factors
- DENALI Part 2 topline data may not meet efficacy endpoints required for accelerated approval
- Competition from other WEE1 inhibitors and emerging therapies in PROC
- Cash runway only into late 2027; may require additional financing before reaching profitability
- Regulatory delays or changes in FDA accelerated approval requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.52 (+31.98%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.52 (+29.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.52 (−32.80%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.52 (−36.20%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.52 (−36.84%) |
Apr 17, 2026 24w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.52 (−45.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access